{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:21:35Z","timestamp":1790299295849,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.parkreldis.2020.08.028","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T04:49:44Z","timestamp":1598417384000},"page":"110-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and \u201cOFF\u201d episodes"],"prefix":"10.1016","volume":"79","author":[{"given":"Jennifer S.","family":"Hui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan H.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Neeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parul","family":"Bhargava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Pappert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradford","family":"Navia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2020.08.028_bib1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1212\/WNL.0b013e3181a1d44c","article-title":"The scientific and clinical basis for the treatment of Parkinson disease","volume":"72","author":"Olanow","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.08.028_bib2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41531-018-0058-0","article-title":"for the Parkinson\u2019s Foundation P4 Group, Prevalence of Parkinson\u2019s disease across North America","volume":"4","author":"Marras","year":"2018","journal-title":"NPJ Parkinsons Dis."},{"key":"10.1016\/j.parkreldis.2020.08.028_bib3","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/pgmj.2003.013912","article-title":"Long term motor complications of levodopa: clinical features, mechanisms, and management strategies","volume":"80","author":"Thanvi","year":"2004","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.parkreldis.2020.08.028_bib4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/mds.23462","article-title":"NMSS Validation Group, The impact of non-motor symptoms on health-related quality of life of patients with Parkinson\u2019s disease","volume":"26","author":"Martinez-Martin","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.08.028_bib5","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/mds.20279","article-title":"Impact of the motor complications of Parkinson's disease on the quality of life","volume":"20","author":"Chapuis","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.08.028_bib6","series-title":"APO-go Pen 10mg\/ml solution for injection","year":"2018"},{"key":"10.1016\/j.parkreldis.2020.08.028_bib7","series-title":"APOKYN\u00ae (apomorphine hydrochloride injection)","year":"2020"},{"key":"10.1016\/j.parkreldis.2020.08.028_bib8","series-title":"MOVAPO (apomorphine hydrochloride injection)","year":"2016"},{"key":"10.1016\/j.parkreldis.2020.08.028_bib9","series-title":"KYNMOBITM (apomorphine hydrochloride) sublingual film","year":"2020"},{"key":"10.1016\/j.parkreldis.2020.08.028_bib10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1474-4422(19)30396-5","article-title":"Apomorphine sublingual film for off episodes in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled phase 3 study","volume":"19","author":"Olanow","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2020.08.028_bib11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/mdc3.12350","article-title":"Apomorphine subcutaneous injection for the management of morning akinesia in Parkinson's disease","volume":"4","author":"Isaacson","year":"2017","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.parkreldis.2020.08.028_bib12","series-title":"Presented at: 5th European Academy of Neurology Congress, June 29\u2013July 2","article-title":"Comparative bioavailability of apomorphine sublingual film and subcutaneous apomorphine formulations in patients with Parkinson's disease and off episodes","author":"Agbo","year":"2019"},{"key":"10.1016\/j.parkreldis.2020.08.028_bib13","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1001\/archneur.58.9.1385","article-title":"A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events","volume":"58","author":"Dewey","year":"2001","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.parkreldis.2020.08.028_bib14","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/jnnp.53.2.96","article-title":"Subcutaneous apomorphine in the treatment of Parkinson's disease","volume":"53","author":"Frankel","year":"1990","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2020.08.028_bib15","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1212\/WNL.52.2.428","article-title":"Yawning in Parkinson's disease","volume":"52","author":"O'Sullivan","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.08.028_bib16","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/jnnp.53.11.1004","article-title":"Comparison of motor response to apomorphine and levodopa in Parkinson's disease","volume":"53","author":"Kempster","year":"1990","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2020.08.028_bib17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00002826-199704000-00008","article-title":"Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study","volume":"20","author":"Merello","year":"1997","journal-title":"Clin. Neuropharmacol."}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802020306945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802020306945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T08:48:34Z","timestamp":1774860514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802020306945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":17,"alternative-id":["S1353802020306945"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2020.08.028","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and \u201cOFF\u201d episodes","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2020.08.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}